Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hepatology
Asıl Yazarlar: Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573922/
https://ncbi.nlm.nih.gov/pubmed/28128852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29081
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller